CTLA41g: Bridging the basic immunology with clinical application

被引：219

作者：

Bluestone, JA ^{[1
]}

St Clair, EW

Turka, LA

机构：

[1] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, Immune Tolerance Network, San Francisco, CA 94143 USA

[3] Duke Univ, Med Ctr, Div Rheumatol & Immunol, Durham, NC 27708 USA

[4] Univ Penn, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA

来源：

IMMUNITY | 2006年 / 24卷 / 03期

关键词：

D O I：

10.1016/j.immuni.2006.03.001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

After a very long and windy road, in December of 2005 the FDA approved CTLA4lg for the treatment of rheumatoid arthritis. Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4lg development and the clinical challenges in bringing the drug from the bench to the bedside.

引用

页码：233 / 238

页数：6

共 46 条

[1] CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Abrams, JR
Lebwohl, MG
Guzzo, CA
Jegasothy, BV
Goldfarb, MT
Goffe, BS
Menter, A
Lowe, NJ
Krueger, G
Brown, MJ
Weiner, RS
Birkhofer, MJ
Warner, GL
Berry, KK
Linsley, PS
Krueger, JG
Ochs, HD
Kelley, SL
Kang, SW
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) : 1243 - 1252
[2] Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
Abrams, JR
Kelley, SL
Hayes, E
Kikuchi, T
Brown, MJ
Kang, SW
Lebwohl, MG
Guzzo, CA
Jegasothy, BV
Linsley, PS
Krueger, JG
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (05) : 681 - 693
[3] Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival
Adams, AB
Shirasugi, N
Jones, TR
Durham, MM
Strobert, EA
Cowan, S
Rees, P
Hendrix, R
Price, K
Kenyon, NS
Hagerty, D
Townsend, R
Hollenbaugh, D
Pearson, TC
Larsen, CP
[J]. JOURNAL OF IMMUNOLOGY, 2005, 174 (01) : 542 - 550
[4] Boden Elisa, 2003, Novartis Found Symp, V252, P55
[5] Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice
Bour-Jordan, W
Thompson, HL
Bluestone, JA
[J]. JOURNAL OF IMMUNOLOGY, 2005, 175 (09) : 5649 - 5655
[6] A NEW MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY - CTLA-4
BRUNET, JF
DENIZOT, F
LUCIANI, MF
ROUXDOSSETO, M
SUZAN, M
MATTEI, MG
GOLSTEIN, P
[J]. NATURE, 1987, 328 (6127) : 267 - 270
[7] CLONING OF B7-2 - A CTLA-4 COUNTER-RECEPTOR THAT COSTIMULATES HUMAN T-CELL PROLIFERATION
FREEMAN, GJ
GRIBBEN, JG
BOUSSIOTIS, VA
NG, JW
RESTIVO, VA
LOMBARD, LA
GRAY, GS
NADLER, LM
[J]. SCIENCE, 1993, 262 (5135) : 909 - 911
[8] B-CELL SURFACE ANTIGEN-B7 PROVIDES A COSTIMULATORY SIGNAL THAT INDUCES T-CELLS TO PROLIFERATE AND SECRETE INTERLEUKIN-2
GIMMI, CD
FREEMAN, GJ
GRIBBEN, JG
SUGITA, K
FREEDMAN, AS
MORIMOTO, C
NADLER, LM
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (15) : 6575 - 6579
[9] The B7 family revisited
Greenwald, RJ
Freeman, GJ
Sharpe, AH
[J]. ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 : 515 - 548
[10] CTLA-4-Ig regulates tryptophan catabolism in vivo
Grohmann, U
Orabona, C
Fallarino, F
Vacca, C
Calcinaro, F
Falorni, A
Candeloro, P
Belladonna, ML
Bianchi, R
Fioretti, MC
Puccetti, P
[J]. NATURE IMMUNOLOGY, 2002, 3 (11) : 1097 - 1101

← 1 2 3 4 5 →